title: Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.
abstract: OBJECTIVE
  To determine (a) the expression of plasma cell related antigens in extranodal marginal zone B cell lymphomas (EMZL) of the ocular adnexa; and (b) the prognostic value of plasmacellular differentiation in these tumours.
  
  
  METHODS
  A consecutive case series of 136 ocular adnexal EMZL obtained from three ocular pathology centres over 20 years was analysed retrospectively. An extensive immunohistochemical panel, including the plasma cell related antigens VS38c, CD38, CD138, multiple myeloma oncogene-1-protein (MUM1/IRF4), and CREB binding protein (CBP) was performed. EMZL were defined as "plasmacellular differentiated" on the basis of morphological features, evidence of cytoplasmic immunoglobulin, negativity for BSAP/PAX5, and expression of at least one of the investigated plasma cell related antigens. Controls included normal or hyperplastic lymphatic tissues. Detailed clinical data were collected for most patients, and compared with the results of immunohistochemistry. The end points considered for statistical analysis were development of local tumour recurrence, development of systemic disease, and lymphoma related death.
  
  
  RESULTS
  57 (42%) of the 136 ocular adnexal EMZL showed a plasmacellular differentiation; 45 of these plasmacytoid cases were primary tumours. In contrast with most admixed normal plasma cells, which displayed co-expression of MUM1/IRF4, Vs38c, CD38, CD138, and CBP, the plasmacellular differentiated EMZL tumour cells demonstrated co-expression of all five plasma cell related antigens in only six of 57 (11%) plasmacellular differentiated ocular adnexal EMZL. The most commonly expressed plasma cell related antigen was MUM1/IRF4, immunoreactivity being seen in 56/57 (98%) plasmacellular differentiated EMZL examined. Although the association of plasmacellular differentiation in primary ocular adnexal EMZL and disseminated disease was statistically significant on univariate analysis (p = 0.042), this was weaker on multivariate analysis.
  
  
  CONCLUSIONS
  Plasmacellular differentiated tumour cells in EMZL demonstrate an aberrant immune profile for plasma cell related antigens when compared with normal plasma cells. On multivariate analysis, plasmacellular differentiation in ocular adnexal EMZL was not significantly associated with local recurrence, the development of systemic disease, or with lymphoma related death.
authors.affiliation: Department of Pathology, Charité-Medical Faculty Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D-12203 Berlin, Germany. sarah.coupland@charite.de
authors.forename: S E
authors.initials: SE
authors.lastname: Coupland
authors.forename: M
authors.initials: M
authors.lastname: Hellmich
authors.forename: C
authors.initials: C
authors.lastname: Auw-Haedrich
authors.forename: W R
authors.initials: WR
authors.lastname: Lee
authors.forename: I
authors.initials: I
authors.lastname: Anagnostopoulos
authors.forename: H
authors.initials: H
authors.lastname: Stein
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D000368:Aged; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D001324:Autoantigens / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D050882:CREB-Binding Protein; D016022:Case-Control Studies; D002454:Cell Differentiation; D004268:DNA-Binding Proteins / Q000032:analysis; D005134:Eye Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D050835:Interferon Regulatory Factors; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis; D008875:Middle Aged; D015999:Multivariate Analysis; D009687:Nuclear Proteins / Q000032:analysis; D010950:Plasma Cells / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D011509:Proteoglycans / Q000032:analysis; D012189:Retrospective Studies; D053668:Syndecan-1; D053667:Syndecans; D015534:Trans-Activators / Q000032:analysis; D014157:Transcription Factors / Q000032:analysis; D000099218:Interferon Regulatory Factor-4
chemical_list: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D001324:Autoantigens; D014408:Biomarkers, Tumor; D050882:CREB-Binding Protein; D004268:DNA-Binding Proteins; D050835:Interferon Regulatory Factors; D008562:Membrane Glycoproteins; D009687:Nuclear Proteins; D011509:Proteoglycans; D053668:Syndecan-1; D053667:Syndecans; D015534:Trans-Activators; D014157:Transcription Factors; D000099218:Interferon Regulatory Factor-4; C508241:SDC1 protein, human; C100347:VS38 monoclonal antibody; C494363:CREBBP protein, human; C498154:CD38 protein, human
references.citation: Am J Surg Pathol. 2000 Jun;24(6):846-52
references.pmid: 10843287
references.citation: Blood. 1999 Jul 15;94(2):701-12
references.pmid: 10397737
references.citation: Br J Ophthalmol. 2001 Jan;85(1):63-9
references.pmid: 11133714
references.citation: Mod Pathol. 2001 Jul;14(7):641-9
references.pmid: 11454995
references.citation: Mod Pathol. 2001 Jul;14(7):686-94
references.pmid: 11455001
references.citation: J Pathol. 2002 Jul;197(3):333-40
references.pmid: 12115879
references.citation: Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90
references.pmid: 12431695
references.citation: Blood. 2002 Dec 15;100(13):4671-5
references.pmid: 12393648
references.citation: Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):130-45
references.pmid: 14685876
references.citation: Ophthalmology. 1978 Aug;85(8):818-43
references.pmid: 101924
references.citation: J Histochem Cytochem. 1981 Apr;29(4):577-80
references.pmid: 6166661
references.citation: J Histochem Cytochem. 1984 Feb;32(2):219-29
references.pmid: 6198355
references.citation: Hematol Oncol. 1989 Jan-Feb;7(1):19-35
references.pmid: 2909457
references.citation: Trans Am Ophthalmol Soc. 1989;87:420-42; discussion 442-4
references.pmid: 2562543
references.citation: Genes Dev. 1990 May;4(5):849-59
references.pmid: 2116362
references.citation: Hum Pathol. 1990 Sep;21(9):959-73
references.pmid: 2394438
references.citation: Cell Regul. 1989 Nov;1(1):27-35
references.pmid: 2519615
references.citation: Am J Clin Pathol. 1993 Apr;99(4):472-85
references.pmid: 8475914
references.citation: Annu Rev Immunol. 1994;12:117-39
references.pmid: 8011279
references.citation: Blood. 1994 Sep 1;84(5):1361-92
references.pmid: 8068936
references.citation: Arch Ophthalmol. 1994 Sep;112(9):1207-12
references.pmid: 8085964
references.citation: J Pathol. 1994 Aug;173(4):371-9
references.pmid: 7965396
references.citation: FASEB J. 1996 Oct;10(12):1408-17
references.pmid: 8903511
references.citation: Ophthalmology. 1995 Dec;102(12):1994-2006
references.pmid: 9098307
references.citation: Semin Immunol. 1997 Aug;9(4):229-34
references.pmid: 9237928
references.citation: Eur J Cancer. 1997 Nov;33(13):2273-7
references.pmid: 9470818
references.citation: Ophthalmology. 1998 Aug;105(8):1430-41
references.pmid: 9709754
references.citation: Ann Oncol. 1998 Jul;9(7):779-81
references.pmid: 9739446
references.citation: J Clin Oncol. 1999 Sep;17(9):2847-53
references.pmid: 10561361
references.citation: Leuk Res. 2000 Feb;24(2):153-9
references.pmid: 10654451
references.citation: Blood. 2000 Mar 15;95(6):2084-92
references.pmid: 10706878
references.citation: Leukemia. 2000 Mar;14(3):449-56
references.pmid: 10720141
references.citation: J Biol Regul Homeost Agents. 1998 Jul-Sep;12(3):81-91
references.pmid: 9795836
references.citation: Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S126-32
references.pmid: 9894477
references.citation: Br J Haematol. 1999 Jan;104(1):138-43
references.pmid: 10027726
references.citation: Leuk Lymphoma. 1999 Feb;32(5-6):533-43
references.pmid: 10048426
references.citation: Pathol Biol (Paris). 1999 Feb;47(2):119-27
references.pmid: 10192879
references.citation: Semin Hematol. 1999 Apr;36(2):139-47
references.pmid: 10319382
references.citation: Ophthal Plast Reconstr Surg. 1999 May;15(3):171-9
references.pmid: 10355835
references.citation: Br J Ophthalmol. 2000 Aug;84(8):907-13
references.pmid: 10906102